Eduardo Cruz Pareja, MD | |
2637 Midpoint Dr, Fort Collins, CO 80525-4407 | |
(970) 488-1666 | |
Not Available |
Full Name | Eduardo Cruz Pareja |
---|---|
Gender | Male |
Speciality | Hospitalist |
Experience | 15 Years |
Location | 2637 Midpoint Dr, Fort Collins, Colorado |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1568759306 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | DR.0060588 (Colorado) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Poudre Valley Hospital | Fort collins, CO | Hospital |
Medical Center Of The Rockies | Loveland, CO | Hospital |
Uchealth Greeley Hospital | Greeley, CO | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Northern Colorado Hospitalists Professional Llc | 8325147507 | 68 |
News Archive
Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.
Every day, women face a barrage of headlines about breast cancer. What should they do with all of that information?
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.
A new study which has analysed 40 years of international research has revealed that maintaining a healthy weight is essential to preventing cancer.
› Verified 3 days ago
Entity Name | Pathways Hospice |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1063444305 PECOS PAC ID: 7911914577 Enrollment ID: O20060307000795 |
News Archive
Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.
Every day, women face a barrage of headlines about breast cancer. What should they do with all of that information?
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.
A new study which has analysed 40 years of international research has revealed that maintaining a healthy weight is essential to preventing cancer.
› Verified 3 days ago
Entity Name | Northern Colorado Hospitalists Professional Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1831315662 PECOS PAC ID: 8325147507 Enrollment ID: O20070628000638 |
News Archive
Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.
Every day, women face a barrage of headlines about breast cancer. What should they do with all of that information?
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.
A new study which has analysed 40 years of international research has revealed that maintaining a healthy weight is essential to preventing cancer.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Eduardo Cruz Pareja, MD 2637 Midpoint Dr Ste B, Fort Collins, CO 80525-4408 Ph: (970) 488-1666 | Eduardo Cruz Pareja, MD 2637 Midpoint Dr, Fort Collins, CO 80525-4407 Ph: (970) 488-1666 |
News Archive
Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.
Every day, women face a barrage of headlines about breast cancer. What should they do with all of that information?
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.
A new study which has analysed 40 years of international research has revealed that maintaining a healthy weight is essential to preventing cancer.
› Verified 3 days ago
Dr. Jennifer Levy Woelk, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2637 Midpoint Dr Ste B, Fort Collins, CO 80525 Phone: 970-488-1666 Fax: 970-472-9381 | |
Victoria Anne Clipsham, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2637 Midpoint Dr Ste B, Fort Collins, CO 80525 Phone: 970-488-1666 Fax: 970-472-9381 | |
Dr. Nancy Terrell Maller, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2637 Midpoint Dr Ste B, Fort Collins, CO 80525 Phone: 970-488-1666 Fax: 970-472-9381 | |
Mrs. Kelly Elizabeth Mistry, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2637 Midpoint Dr Ste B, Fort Collins, CO 80525 Phone: 434-243-4394 Fax: 434-243-4873 | |
Dr. Rebecca Rain Jackson, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1032 Luke St Ste 1, Fort Collins, CO 80524 Phone: 970-568-5810 | |
Dr. Nathan Michael Smith, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2637 Midpoint Dr Ste B, Fort Collins, CO 80525 Phone: 970-488-1666 |